Skin · Nov 10, 2026

Impact of GLP-1 Receptor Agonist Therapy on Outcomes in Hidradenitis Suppurativa: A TriNetX Database Study

By Frisbie S, Phuyal D, Brito E et al.

Background: Hidradenitis Suppurativa is a chronic inflammatory disorder strongly associated with obesity and metabolic dysfunction.1 Glucagon-like peptide-1 receptor agonists (GLP-1RA) demonstrate weight-loss and anti-inflammatory effects that may influence postoperative healing.1-3 We evaluated postoperative complications following hidradenitis excision among patients receiving GLP-1RA therapy compared with non-users. Methods: This retrospective cohort study analyzed patients within the TriNetX database, aggregating electronic medical records and claims data from 70 healthcare organizations representing over 101 million patients. Included patients underwent hidradenitis excision involving the axillary (CPT-11450, CPT-11451), perianal/perineal/umbilical (CPT-11470, CPT-11471), or inguinal regions (CPT-11462, CPT-11463). Cohorts were stratified by preoperative GLP-1RA use, including Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, or Exenatide, prescribed up to one day prior to surgery. One-to-one propensity score matching was performed for age, sex, race, ethnicity, comorbidities, HS-related procedures, and immunosuppressive therapy. Outcomes assessed at 1 and 3 months postoperatively included infection, debridement, reoperation, wound dehiscence, sepsis, thromboembolic events, emergency department visits, and overall complications. Reoperation was defined as repeat hidradenitis excision occurring ≥1 day after index surgery. Results: After propensity score matching, 2,992 patients were included (1,496 per cohort), with balanced baseline characteristics (standardized mean differences <0.1). GLP-1RA users demonstrated significantly lower rates of reoperation at 1 month (2.0% vs 3.5%; risk ratio [RR], 0.58; 95% confidence interval [CI], 0.37-0.90; P=0.014) and 3 months (4.4% vs 6.3%; RR, 0.70; 95% CI, 0.52-0.95; P=0.023) compared with non-users. However, GLP-1RA users demonstrated significantly higher rates of postoperative infection at 1 month (7.4% vs 5.2%; RR, 1.41; 95% CI, 1.06-1.87; P=0.016). Rates of debridement, wound dehiscence, thromboembolic events, emergency department visits, and overall complications were otherwise similar between cohorts. Conclusion: GLP-1RA therapy was associated with reduced postoperative reoperation following HS excision despite increased short-term infection rates. The increased infection risk may partially reflect the greater underlying metabolic disease burden among patients prescribed GLP-1RAs. Overall complication profiles were otherwise comparable, supporting a potential perioperative role for GLP-1RAs in patients undergoing surgical management of HS. Further prospective studies are needed to better define the relationship between GLP-1RA therapy, wound healing, and postoperative outcomes.

doi.org/10.25251/5swch621Open accessInterventions

AgingResearch.News